, marketed under the names Marsilid
) is a monoamine oxidase inhibitor (MAOI
) that was developed as the first anti-depressant.
It is an irreversible inhibitor.
It was originally intended to treat tuberculosis
when it was discovered that patients given iproniazid became "inappropriately happy". Subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic
drugs, particularly isocarboxazid